LifeStance Health Group shares rise following Barclays upgrade

LifeStance Health Group shares rose over 3.5% following an upgrade from Barclays, which raised its price target for the stock from $13.00 to $15.00. Analysts noted that a recent shareholders’ offering helps reduce the overhang associated with private equity ownership.

In a broader healthcare sector movement, Orchestra BioMed also saw significant gains after BTIG upgraded the company to ‘Buy’ from ‘Neutral’. The upgrade follows progress in the company’s Backbeat clinical trial, a hypertension study conducted in partnership with Medtronic, which remains on track to complete enrollment by the end of the third quarter.